Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

70
Antares Pharma Appoints Dr. James Tursi Executive Vice President, Head of Research & Development, Chief Medical Officer

2018-08-06 globenewswire
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James P. Tursi M.D. to the position of Executive Vice President, Head of Research & Development, Chief Medical Officer effective August 6, 2018. Dr. Tursi has a diversified corporate background including 15 years of drug development experience within the biotech and pharmaceutical industry.
ATRS AMAG TEVJF ARLZ AGRX POZN TEVA TEVVF AUXL

65
ARLZ / Aralez Pharmaceuticals Inc. / Flynn James E - null (Passive Investment)

2018-06-25 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102)
ARLZ

70
ARLZ / Aralez Pharmaceuticals Inc. / Flynn James E - null (Passive Investment)

2018-06-25 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102)
ARLZ

66
Update On Aralez Pharmaceuticals

2018-06-18 seekingalpha
On May 8th Aralez announced it was discontinuing its U.S. operations, slashing costs, selling certain US assets, and focusing on its Cdn.business supported by Vimovo royalties & its Toprol franchise.
ARLZ TRX

86
ARLZ / Aralez Pharmaceuticals Inc. DEFA14A

2018-05-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ARLZ

74
ARLZ / Aralez Pharmaceuticals Inc. DEF 14A

2018-05-18 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2
ARLZ

67
Aralez Pharmaceuticals: Change In Strategy May Bring A Silver Lining

2018-05-11 seekingalpha
Despite announcing record Q1 2018 revenues, Aralez announced a new strategic direction; discontinuing its U.S. commercial operations; slashing operating expenses to $25MM per annum (from $22MM in Q1 alone).
ARLZ TRX

412
Your Daily Pharma Scoop: Akcea-Ionis Ad Com, Aralez U.S. Shut Down, Lynparza EU Approval

2018-05-09 seekingalpha
Ionis (NASDAQ:IONS) subsidiary Akcea (NASDAQ:AKCA) has an Ad Comm today, May 10, for its volanesoren as an adjunct to diet for the treatment of patients with familial chylomicronemia syndrome. That is a rare disease, and this is an antisense drug. Antisense is Ionis’s contribution, more or less, to medicine. It is a technology, briefly put, where a protein binds to mRNAs and stops them from producing harmful proteins.
AZN BLPH AZN ARLZ MRK IONS VRX ONCS AKCA RLYP ALNY

90
ARLZ / Aralez Pharmaceuticals Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
arlz_Current_Folio_10Q Table of Contents
ARLZ

ARLZ : Aralez Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Aralez is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Its parent corporation, Aralez Pharmaceuticals Inc., was incorporated under the British Columbia Business Corporations Act (“BCBCA”) on December 2, 2015. its global headquarters is located in Mississauga, Ontario, Canada, its U.S. headquarters is located in Princeton, New Jersey, United States, and its Irish headquarters is located in Dublin, Ireland. Aralez was formed for the purpose of facilitating the business combination of POZEN Inc., a Delaware corporation (“Pozen”), and Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (“Tribute”), which transaction closed on February 5, 2016. On February 5, 2016, pursuant to an Agreement and Plan of Merger and Arr...

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 03852X100